Prognostic Significance of Increased Serum Bilirubin Levels Coincident With Cardiac Decompensation in Chronic Heart Failure
|
|
- Mavis Henry
- 6 years ago
- Views:
Transcription
1 Circ J 28; 72: Prognostic Significance of Increased Serum Bilirubin Levels Coincident With Cardiac Decompensation in Chronic Heart Failure Hisahito Shinagawa, MD; Takayuki Inomata, MD; Toshimi Koitabashi, MD; Hironari Nakano, MD; Ichiro Takeuchi, MD; Takashi Naruke, MD; Tsutomu Ohsaka, MD; Mototsugu Nishii, MD; Hitoshi Takehana, MD; Tohru Izumi, MD Background The aim of this study was to analyze the relationship between abnormal liver function tests (LFTs) coincident with heart failure (HF) exacerbation and subsequent long-term outcome in patients with chronic HF. Methods and Results The study population consisted of 183 consecutive patients admitted for HF exacerbation with left ventricular ejection fraction 4%. Cox proportional hazard analysis revealed that serum total bilirubin (T-Bil) levels on admission (hazard ratio 1.896, p<.1, 95%confidence interval ), but not T-Bil at discharge or other LFTs, was an independent predictor of subsequent cardiac events after hospital discharge (cardiac death or readmission for HF exacerbation) The cardiac-event-free rates significantly decreased according to increasing tertiles of T-Bil stratified by the level of.7 and 1.2mg/dl (p<.1). T-Bil on admission had significant correlations with simultaneously-measured central venous pressure (CVP) (r=.42, p<.1) and cardiac index (CI) (r=.5, p<.1). The patients demonstrating high CVP together with low CI showed significantly increased T-Bil compared with any other group. Conclusions Increased T-Bil coincident with cardiac decompensation predicts a worse long-term prognosis of CHF, presumably through the potential liability to both congestion and tissue hypoperfusion simultaneously when HF deteriorates. (Circ J 28; 72: ) Key Words: Acute exacerbation; Bilirubin; Heart failure; Liver function test; Prognosis Liver dysfunction has long been reported as 1 of the remarkable phenomena caused by heart failure (HF). 1 5 It is considered that both congestion and low perfusion of the liver, reflecting impaired hemodynamics, are the causative mechanisms. 2 5 This consistency in the mechanism of liver dysfunction and the pathogenesis contributing to severe HF implies that a liver function abnormality could have a prognostic impact on patients with chronic HF. The prognosis of chronic HF based on the serum levels of aspartate aminotransferase (AST) and bilirubin (Bil) has been reported, 1 but it is necessary to interpret the data from liver function tests (LFTs) according to the sampling time-points during the course of exacerbated HF, because abnormal LFTs are known to fluctuate and resolve rapidly coincident with compensation of HF. 3,5 The aim of this study was to analyze the relationship between the abnormal profile of LFTs coincident with HF exacerbation and subsequent long-term outcome of chronic HF. (Received June 11, 27; revised manuscript received November 5, 27; accepted November 13, 27) Department of Cardio-angiology, Kitasato University School of Medicine, Sagamihara, Japan Mailing address: Hisahito Shinagawa, MD, Department of Cardioangiology, Kitasato University School of Medicine, Kitasato, Sagamihara , Japan. hisahito@med.kitasato-u.ac.jp All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp Methods Study Population Chronic HF patients who were admitted to Kitasato University Hospital for HF exacerbation with left ventricular ejection fraction (LVEF) 4% from January 1999 to December 22 were consecutively recruited. Patients with acute coronary syndrome, acute myocarditis, hepatobiliary diseases, chronic renal dysfunction (serum creatinine levels >2. mg/dl), active malignancy, or drug-induced liver dysfunction were excluded. From 188 recruits, the final study population comprised 183 patients (5 patients died in hospital) who would be followed after hospital discharge. Endpoints, defined as readmission for HF exacerbation or cardiovascular death (termed as cardiac events ) after hospital discharge, were retrospectively analyzed until September 25. HF exacerbation was judged by at least 2 experienced cardiologists according to the Framingham criteria, 6 together with other clinical data including chest X-rays and echocardiography. All patients gave informed consent and the study procedure was in compliance with the institutional guidelines of Kitasato University and the principles outlined in the Helsinki Declaration. Clinical Evaluation and Hemodynamic Measurements Biochemical laboratory data, New York Heart Association functional class (NYHA class), and echocardiography were evaluated on admission and at discharge. Arterial blood gas analysis was performed on admission. All clinical findings at discharge were sampled from the latest data to discharge when HF was adequately controlled. Plasma Circulation Journal Vol.72, March 28
2 Prognostic Significance of Bil for Chronic HF 365 Table 1 Patients Characteristics All patients (n=183) Patients characteristics according to T-Bil on admission Low <.7 mg/dl Intermediate.7 High 1.2 mg/dl (n=66) <1.2 mg/dl (n= 65) (n= 52) p value* Age, years (IQR) 66 (58 75) 67 (59 76) 66 (57 75) 66 (54 74).63 Male, n (%) 13 (71) 45 (68.1) 43 (66.1) 42 (8.7).18 Data on admission NYHA class II:III:IV, n 9:53:121 3:16:47 4:19:42 2:19:31.8 SBP, mmhg (IQR) 13 ( ) 14 ( ) 132 ( ) 118 (16 14) <.1 DBP, mmhg (IQR) 8 (68 88) 91 (81 11) 78 (68 86) 77 (64 88).21 Heart rate, beats/min (IQR) 1 (84 118) 16 (88 12) 96 (8 114) 1 (78 119).16 LVEF,% (IQR) 29 (24 36) 3. ( ) 29. ( ) 27 ( ).56 LVDd, mm (IQR) 61 (55 68) 59 (52 68) 6 (55 67) 65 (56 7).65 T-Bil, mg/dl (IQR).8 (.6 1.2).5 (.3.6).9 (.8 1.) 1.5 ( ) <.1 D-Bil, mg/dl (IQR).4 (.3.4).2 (.2.3).3 (.3.4).7 (.5.9) <.1 AST, U/L (IQR) 36 (27 61) 34 (23 52) 39 (27 65) 4 (29 68).18 ALT, U/L (IQR) 29 (19 57) 26 (17 4) 31 (21 7) 35 (21 55).33 ALP, U/L (IQR) 25 ( ) 176 ( ) 188 ( ) 221 ( ).91 LDH, U/L (IQR) 57 (47 73) 547 (271 73) 567 (485 73) 622 (462 76).364 GTP, U/L (IQR) 71 (42 78) 38 (25 59) 61 (32 81) 73 (4 138).33 Creatinine, mg/dl (IQR) 1. (.8 1.3) 1.7 (.8 1.2) 1. ( ) 1.1 ( ).321 Serum sodium, mmol/l (IQR) 139 ( ) 139 ( ) 139 ( ) 138 ( ).5 BNP, pg/ml (IQR) 558 (36 96) 598 (32 9) 54 (35 85) 685 (559 1,26).6 Data at discharge NYHA class I:II:III:IV, n 58:13:17: 5 26:36:4: 19:38:6:2 13:29:7:3.28 LVEF, % (IQR) 37 (32 42) 37 (35 4) 37 (34 44) 36 (28 42).6 T-Bil, mg/dl (IQR).6 (.4.8).5 (.4.6).6 (.5.7).7 (.6.9).15 Creatinine, mg/dl (IQR) 1.1 (.8 1.2) 1.8 (.8 1.2) 1.14 (.8 1.2) 1.14 ( ) <.1 BNP, pg/ml (IQR) 174 (73 27) 162 (59 21) 15 (52 279) 194 (16 35).17 *p value among the tertiles stratified by T-Bil on admission. T-Bil, total bilirubin; IQR, interquartile range; NYHA class, New York Heart Association functional class; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; LVDd, left ventricular diastolic diameter; D-Bil, dilect birilubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; GTP, glutamyl transferase; BNP, plasma B-type natriuretic peptide. B-type natriuretic peptide (BNP) was determined by sensitive noncompetitive immunoradiometric assays (Shionoria BNP, Shionogi, Osaka, Japan) using venous blood samples taken after 15 min of rest. Echocardiography was undertaken transthoracically using ProSound SSD-5 (ALOKA, Tokyo, Japan). M-mode images were obtained in the left parasternal long-axis views to measure each chamber dimension, and LVEF was calculated by the modified Simpson s method using biplane images from apical viewpoints. Right heart catheterization was performed on admission using Swan-Ganz catheters in 79 patients who were judged by individual chief physicians to require hemodynamic monitoring of central venous pressure (CVP), pulmonary artery wedge pressure (PAWP), and cardiac index (CI) determined by the Fick method. Statistical Analysis In order to investigate independent predictor(s) of cardiac events, clinical variables with a p-value <.5 in the univariate analysis were examined using multivariate analysis in a Cox proportional hazard model. The selection method was a forward selection with a significance level of.5 for entering an explanatory variable into the model. The final model only included significant variables with a p-value <.5 using the Wald test. The cardiac-event-free rates among the tertiles based on total Bil (T-Bil) levels on admission or at discharge were compared using Kaplan-Meier analysis with a log-rank test. Comparisons among groups of the patients characteristics were performed using a chisquared test for categorical variables, and the Mann-Whitney U-test or Kruskal Wallis rank test for continuous variables, followed by the Scheffe s method for multiple comparisons if necessary. Correlation coefficients between T-Bil and hemodynamic variables were tested with Spearman s rankcorrelation test. Continuous variables are presented as median and interquartile range or mean ± standard deviation. For all analyses, a 2-sided p-value <.5 was considered as statistically significant. The statistical package used was SPSS 11..1J for Windows (SPSS Inc, Chicago, IL, USA). Results Patients Characteristics and Subsequent Events During Follow-up The mean age of the patients was 65.4±14.2 years and 71% were men. Underlying disorders were ischemic heart disease (49%), dilated cardiomyopathy (29%), valvular heart disease (25%); a history of hypertension (45%), diabetes mellitus (38%), and hyperlipidemia (16%). Other characteristics are listed in Table 1. Cardiac events occurred in 44% (81/183) of the subjects during the follow-up period (29.5±2.8 months) and of these 25 were cardiac deaths (13.7%; 16 with HF exacerbation, 6 with lethal ventricular arrhythmias, 2 sudden cardiac deaths, and 1 acute myocardial infarction). Six patients (3.3%) died of other causes, such as pneumonia or malignancy, before the endpoint. Readmission for HF exacerbation occurred in 4% (73/183). Prognostic Significance of Serum T-Bil on Admission Among the clinical parameters on admission, univariate analysis showed that significant predictors were age, male sex, systolic blood pressure (SBP), diastolic blood pressure, heart rate, T-Bil, direct Bil (D-Bil), alkaline phosphatase Circulation Journal Vol.72, March 28
3 366 SHINAGAWA H et al. Table 2 Predictors of Subsequent Cardiac Events Univariate analysis Multivariable analysis HR (95%CI) p value HR (95%CI) p value Age, years 1.49 ( ) < ( ) <.1 Male (vs Female) ( ).17 Data on admission NYHA class.283 SBP, mmhg.979 ( ) < ( ).14 DBP, mmhg.974 ( ) <.1 Heart rate, beats/min.982 ( ) <.1 LVEF, %.342 LVDd, mm.165 T-Bil, mg/dl ( ) < ( ) <.1 D-Bil, mg/dl ( ).2 ALP, U/L 1.4 ( ).9 GTP, U/L 1.5 ( ).29 AST, U/L.784 ALT, U/L.761 LDH, U/L.948 Creatinine, mg/dl ( ).9 Serum sodium, mmol/l.716 BNP, pg/ml 1.1 (1. 1.1).2 Data at discharge NYHA class ( ) ( ).28 LVEF.967 ( ).11 T-Bil.889 Creatinine ( ).42 BNP 1.3 ( ) < ( ).1 HR, hazard ratio; CI, confidence interval. Other abbreviations as in Table 1. Cardiac-events-free survival rate (%) Low Intermediate High n patients at risk T-Bil on admission Low (T-Bil <.7 mg/dl) Intermediate (.7 T-Bil <1.2 mg/dl) High (1.2 mg/dl T-Bil) Time after hospital admission (months) p=.36 p=.37 p<.1 Fig 1. Kaplan-Meier survival curves showed a significant difference of subsequent cardiac events among the tertiles stratified with serum total bilirubin (T-Bil) level on admission. (ALP), -glutamyltranspeptidase ( GTP), creatinine, and BNP. At discharge, NYHA class, LVEF, creatinine and BNP concentrations significantly predicted subsequent cardiac events (Table 2). Multivariate analysis revealed that the independent predictors of subsequent cardiac events were T-Bil on admission (hazard ratio 1.896, p<.1, 95% confidence interval ), together with age, SBP on admission; NYHA class and BNP at discharge (Table2). Focusing on the contribution of the serum T-Bil level to the prognosis of HF, patients were divided into tertiles on the basis of T-Bil on admission or at discharge. The cardiacevent-free rates after hospital discharge significantly decreased according to increasing tertiles of T-Bil on admission (low level group: T-Bil <.7mg/dl (12. mol/l), n=66; intermediate:.7 <1.2 mg/dl (2.5 mol/l), n=65; high: 1.2 mg/dl, n=52) (p<.1; Fig 1). In the comparison of Circulation Journal Vol.72, March 28
4 Prognostic Significance of Bil for Chronic HF 367 CI (L min 1 m 2 ) r= p <.1 y = 2.73 x y = -.72 x CVP (mmhg) r=.42 p <.1 PAWP (mmhg) y = 5.89 x r=.41 p <.1 PaO2 (mmhg) r= -.1 p=.43 y = x Fig 2. This chart indicates significant correlations between total bilirubin (T-Bil) on admission and cardiac index (CI), pulmonary artery wedge pressure (PAWP), and central venous pressure (CVP), respectively. 4 3 p<.1 p<.5 p<.5 2 p<.1 for all 1 Group A (n=31) B (n=23) C (n=11) D (n=14) CVP <8 CVP 8 CVP <8 CVP 8 (mmhg) CI 2.2 CI 2.2 CI <2.2 CI <2.2 (L min 1 m 2 ) Fig 3. Among the 4 groups (Group A-D) stratified with the levels of central venous pressure (CVP) and cardiac index (CI), the total bilirubin (T-Bil) level was significantly highest in Group D, in which systemic congestion and low perfusion coexisted. The lines represent the median, the boxes represent the interquartile range, and whiskers represent the 5th and 95th percentiles. the clinical characteristics among these 3 groups, there was no significant difference in the parameters including age, NYHA class, or BNP at discharge, other than SBP on admission (Table 1). Regarding the stratification based on T-Bil at discharge (low: <.5 mg/dl (8.6 mol/l), n=45; intermediate:.5 <.8 mg/dl (1.9 mol/l), n=97; high:.8 mg/dl, n=41), no significant difference in the cardiacevent-free rates after hospital discharge was seen among these tertiles (data not shown). Correlation of T-Bil Level and Hemodynamic Parameters T-Bil level on admission had significant correlations with simultaneously-measured CVP (r=.42, p<.1), PAWP (r=.41, p<.1) and CI (r=.5, p<.1) (Fig 2), but not with the arterial oxygen pressure (PaO2) (r=.1, p=.43; Fig 2). In this clinical setting, oxygen had already been administrated to 5% of patients (92/183) when arterial blood gas was analyzed. Furthermore, we analyzed 91 patients in whom oxygen was not given and there was no significant correlation (r=.1, p=.32) either. Based on the CVP and CI, patients were divided into Circulation Journal Vol.72, March 28
5 368 SHINAGAWA H et al. 4 groups (A: CVP <8mmHg, CI 2.2 L min 1 mm 2 ; B: CVP 8mmHg, CI 2.2L min 1 mm 2 ; C: CVP <8mmHg, CI <2.2L min 1 mm 2 ; D: CVP 8mmHg, CI <2.2L min 1 mm 2 ). T-Bil was significantly highest when systemic congestion and hypoperfusion coexisted, classified as group D, compared with any other group (group A vs D: p<.1, B vs D: p<.5, C vs D: p<.5; Fig 3). Furthermore, a similar relationship was found using PCWP instead of CVP (data not shown). Discussion Pathophysiological Mechanism of Increased Serum Bil Level in HF HF results in a broad range of abnormal LFTs, the most common of which is a mild elevation of serum Bil (3 7% of patients), with increases of other cholestatic markers such as ALP and GTP being milder and less frequent, up to 1 2%, as well as those of the serum transaminases such as AST and alanine aminotransferase (12 33%). 3,7,8 The pathomechanism responsible for the liver injury is considered to be derived from 2 hemodynamic alterations in HF: decreased hepatic blood flow originating from low cardiac output and increased hepatic venous pressure with subsequent atrophy of liver cells and edema of the peripheral area, both leading to hepatocellular hypoxia. 3,7 PaO2 itself is thought to be a minor factor in hepatic injury. 3 Several studies so far have shown that the serum Bil correlates with various hemodynamic parameters, such as right atrial pressure (RAP), 2,4,9 severity of tricuspid regurgitation (TR), 4,9 PAWP, 9 LVEF, 4 and CI, 9 whereas ALP and GTP only do so with RAP 3,8 and the severity of TR. 8 It has never been documented that the transaminases have a correlation with these parameters. 3,8 In our study, LFTs other than Bil did not have a significant correlation with hemodynamic parameters (data not shown). The differences might be explained by the different pathophysiological mechanisms of the increase in each LFT. Several metabolic processes of Bil, including the uptake of indirect Bil from blood, conjugation in hepatocytes 3 and secretion of D-Bil into bile, 1,11 are attenuated by hepatocellular hypoxia, leading to an enhanced increase of the serum T-Bil. Biliary obstruction caused by high hepatic venous pressure is also reported to be a causative mechanism when T-Bil is highly elevated. 8 Furthermore, hemolysis, which occurs mainly in the simply congested lungs of HF patients, leads to an increase in the serum indirect Bil. 2,7,12 It is certain that the levels of transaminases also correlate with hepatocellular hypoxia, but necrosis of the affected hepatocyte is required for an increase in the serum levels, 3 which is the reason why the cells swell dramatically in cases of acute decrease in cardiac output such as cardiogenic shock. 7 The increase in the level of ALP, as well as GTP, is derived mainly from obstruction of the biliary system, 13,14 not through hepatocellular hypoxia. Therefore, Bil is the most sensitive marker among the LFTs for severe HF, as an integral clinical indicator to reflect the multifarious conditions related to HF. Clinical Impact of Serum Bil Level on HF Exacerbation in Relation to Long-Term Prognosis Previous studies have reported conflicting results concerning the clinical significance of measuring the serum T- Bil level as a marker of hemodynamic parameters. It was shown in 1 study of patients with severe HF that the serum T-Bil level had significant correlations with CI, as well as RAP or PAWP, 7 whereas in another study of patients with stable HF the T-Bil correlated only with RAP. 2 In the present study, serum T-Bil levels at the time of HF decompensation had a clearer correlation with CI than either CVP or PAWP (r=.5,.42,.41, respectively) (Fig 2), which suggests that the serum T-Bil level coincident with cardiac decompensation more exactly reflects the hemodynamics, especially CI, compared with when HF is more controlled. Low cardiac output, more frequently coincident with exacerbated HF, may be the key to interpreting the present result that the serum T-Bil on admission, but not at discharge, was an independent predictor of subsequent cardiac events, because low cardiac output can predict HF prognosis better than concomitant pulmonary or systemic congestion. 15 The significance of the serum T-Bil level depends on the type of HF, including disease severity and clinical stage; in other words, it is important to consider the HF status when the clinical significance of the serum T-Bil level is being evaluated. Another point is that the serum Bil at the time of acute decompensation may predict HF outcome in the remote future beyond the acute phase of HF exacerbation, despite the similar HF status at the starting point presumed by the plasma BNP, NYHA class and LVEF values at discharge. However, we can confirm that the serum Bil on admission predicts the patient s prognosis, even when we include the first hospitalization into the follow-up period, changing the starting point of follow-up from hospital discharge to admission (data not shown). Those results suggest that elevation of the serum T-Bil level represents not only the temporary severity of hemodynamics but also the latent cardiac status of chronic HF contributing to long-term prognosis. It seems that the serum T-Bil level at the time of HF exacerbation should be regarded as the marker of the hemodynamic response to deteriorated HF, which reflects cardiac pump/circulatory reserve, leading to differentiation of HF prognosis even among patients with similar HF status during the stable phase. Comparative Characteristics of Bil as an Indicator of HF The plasma BNP level is widely used in general practice as a valuable predictor of HF prognosis. 16,17 Although conflicting data exist, 18 the plasma BNP concentration has a good correlation with filling pressure, 19,2 but there are no data concerning the CI. 19 The serum T-Bil level, on the other hand, reflects the CI as well as congestion, as mentioned earlier. In clinical practice, for HF management it is generally easier to detect congestion than low cardiac output or hypoperfusion. The present study indicates that an increased serum T-Bil level could be a clue to a hypoperfused status in HF patients, leading to adequate therapy without using invasive clinical techniques. Study Limitations The study was carried out inside a single institute in both a retrospective and nonrandomized fashion. The acquired data might be biased because clinical judgment depended on the clinical status of each patient. Furthermore, while it is ideal that there should be no significant differences in clinical background among tertiles in practise this is impossible because the serum Bil levels are determined by pathological and hemodynamic changes. Based on the analysis of the present study, we paid attention to the clinical data on admission that were related to Circulation Journal Vol.72, March 28
6 Prognostic Significance of Bil for Chronic HF the prognosis of HF. Because the time of onset of acute cardiac decompensation leading to hospital admission is imprecise among individual patients, clinical parameters defined as within 24 h of admission might be estimated at different clinical time-points within the variation of HF status, leading to some biased interpretations. Finally, as the present study consisted of patients who had left ventricular systolic dysfunction (LVEF 4%) on admission, further study of patients with preserved systolic function is warranted. Acknowledgments This study was supported in part by grant-in-aid for scientific research from the Integrative Research Program of the Graduate School of Medical Sciences, Kitasato University. References 1. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley J. The importance of abnormality of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995; 16: Sherlock S. The liver in heart failure: Relation of anatomical, functional, and circulatory changes. Br Heart J 1951; 13: Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: A review. Am J Med Sci 1973; 265: Lau GT, Tan HC, Kritharides L. Type of dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 22; 9: Naschitz JE, Slobodin G, Lewis RJ, Zuckermqn E, Yashurun D. Heart disease affecting the liver and liver diseases affecting the heart. Am Heart J 2; 14: Ho KL, Prinsly JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22(Suppl): 6A. 7. Sherlock S, Dooley J. The hepatic artery and hepatic veins: The liver in circulatory failure. In: Sherlock S, Dooley J, editors. Diseases of the liver and biliary system, 11 th edn. Oxford: Blackwell Science; 22; Rosenberg PM, Lawrence SF. The liver in circulatory failure. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Shiff s diseases of the liver, 9 th edn. Philadelphia: Willis C. Maddrey; 23; Kubo SH, Walter BA, John DH, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure: Influence of systemic hemodynamics. Arch Intern Med 1987; 147: Reese AJ. The effect of hypoxia on liver secretion studied by intravital fluorescence microscopy. Br J Exp Pathol 196; 41: Shorey J, Schenker S, Combes B. Effect of acute hypoxia on hepatic excretory function. Am J Physiol 1969; 216: Kramer MR, Marshall SE, Tiroke A, Lewiston NJ, Starnes VA, Theodore J. Clinical significance of hyperbilirubinemia in patients with pulmonary hypertension undergoing heart-lung transplantation. J Heart Lung Transplant 1991; 1: Poynard T, Imbert-Bismut F. Laboratory testing for liver disease. In: Boyer TD, Wright TL, Manns MP, editors. Zakim and Boyer s hepatology: A text book of liver disease, 5 th edn. New York: Elsevier; 26; Richman SM, Delman AJ, Grob D. Alteration in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med 1961; 3: Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 23; 41: McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 22; 16: Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 22; 15: Parsonage WA, Galbraith AJ, Koerbin GL, Potter JM. Value of B- type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 25; 95: Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 9: Circulation Journal Vol.72, March 28
Abnormal Liver Function in Relation to Hemodynamic Profile in Heart Failure Patients
Journal of Cardiac Failure Vol. 16 No. 1 2010 Abnormal Liver Function in Relation to Hemodynamic Profile in Heart Failure Patients V.M. VAN DEURSEN, 1 K. DAMMAN, MD, PhD, 1 H.L. HILLEGE, MD, PhD, 1,2 A.P.
More informationThe Heart in Concert: Do Other Organs Matter? The Liver
The Heart in Concert: Do Other Organs Matter? The Liver Pascal de Groote CHRU Lille France DECLARATION OF CONFLICT OF INTEREST I have no conflict of interest with this presentation Impact of liver disease
More informationStudy of liver biochemical profiles in congestive heart failure patients in Government Dharmapuri Medical College, Dharmapuri
Original Research Article Study of liver biochemical profiles in congestive heart failure patients in Government Dharmapuri Medical College, Dharmapuri P. Ravikumar * Assistant Professor, Department of
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationValue of echocardiography in chronic dyspnea
Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationChange of Exhaled Acetone Concentration Levels in Patients with Acute Decompensated Heart Failure A Preliminary Study
CLINICAL STUDY Change of Exhaled Acetone Concentration Levels in Patients with Acute Decompensated Heart Failure A Preliminary Study Tetsuro Yokokawa, 1 MD, Takamasa Sato, 1 MD, Satoshi Suzuki, 1 MD, Masayoshi
More informationInfluence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion
Influence of Paroxysmal Atrial Fibrillation Attack on Brain Natriuretic Peptide Secretion Keizo Kazuhiko TSUCHIDA,MD TANABE, MD Abstract Objectives. Plasma brain natriuretic peptide BNP concentration is
More informationRandomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure (J-CHF) Study
82th AHA Meeting Nov 17, 2009 Orlando, USA Presenter Disclosure Information Randomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationDisclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
More informationComparison with plasma angiotensin II and endothelin-1
European Heart Journal (1999) 2, 1799 187 Article No. euhj.1999.1746, available online at http://www.idealibrary.com on Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationHeart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.
Introduction: Heart failure (HF) is a complex clinical syndrome that results in the impairment of the heart s ability to fill or to pump out blood. As of 2013, an estimated 5.8 million people in the United
More informationORIGINAL ARTICLE. Abstract. Introduction. Materials and Methods
ORIGINAL ARTICLE Effects of Cardiac Hemodynamics on Agreement in the ph, HCO3- and Lactate Levels between Arterial and Venous Blood Samples in Patients with Known or Suspected Chronic Heart Failure Satoshi
More informationPrognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation
Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation Hidekazu Tsuneoka 1)2), Akira Koike 2), Osamu Nagayama 2), Koji Sakurada 2), Hitoshi Sawada 2), Kazutaka Aonuma
More informationScreening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels
Screening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels Toru SUZUKI, MD, Kazuhide YAMAOKI,MD,OsamuNAKAJIMA, 1 MD, Tsutomu YAMAZAKI, MD, Yoshiharu YAMADA,
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationLeft ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy
Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania My conflicts of interest: I have
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More information5 Important Things to Know About Heart Failure. Kia Afshar, MD
5 Important Things to Know About Heart Failure Kia Afshar, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1) Understand
More informationA study of Brain Natriuretic Peptide levels in acute cardiac failure
Original Research Article A study of Brain Natriuretic Peptide levels in acute cardiac failure Bhavik Prajapati 1*, Anirudh Kulkarni 2 1 Assistant Professor, Department of Medicine, SMS Multispecialty
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationAtrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction
Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction JC Eicher, G Laurent, O Barthez, A Mathé, G Bertaux, JE Wolf Heart Failure Treatment Unit, Rhythmology and
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationAcute impairment of basal left ventricular rotation but not twist and untwist are involved in the pathogenesis of acute hypertensive pulmonary oedema
Acute impairment of basal left ventricular rotation but not twist and untwist are involved in the pathogenesis of acute hypertensive pulmonary oedema A.D. Margulescu 1,2, R.C. Sisu 1,2, M. Florescu 2,
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationPlasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice
Journal of Cardiology (2008) 52, 212 223 ORIGINAL ARTICLE Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice Keizo Tsuchida (MD) a,, Kazuhiko
More informationNatural History and Echo Evaluation of Aortic Stenosis
Natural History and Echo Evaluation of Aortic Stenosis Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM AORTIC STENOSIS First valvular disease
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationClinical Evaluation and Hepatic Laboratory Assessment in Individuals with Congestive Heart Failure
Clinical Evaluation and Hepatic Laboratory Assessment in Individuals with Congestive Heart Failure Luiz Antônio Brito Arruda Vasconcelos, Eros Antônio de Almeida, Luiz Felipe Bachur Universidade Estadual
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationPlasma Brain Natriuretic Peptide as a Noninvasive Marker for Efficacy of Pulmonary Thromboendarterectomy
Plasma Brain Natriuretic Peptide as a Noninvasive Marker for Efficacy of Pulmonary Thromboendarterectomy Noritoshi Nagaya, MD, Motomi Ando, MD, Hideo Oya, MD, Yutaka Ohkita, MD, Shingo Kyotani, MD, Fumio
More information*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND
USE OF N-TERMINAL NATRIURETIC PEPTIDE IN A REAL- WORLD SETTING OF PATIENTS ADMITTED WITH ACUTE DYSPNOEA AND THE IMPLICATION FOR TRIAGING PATIENTS IN THE EMERGENCY DEPARTMENT *Christian M. Carlsen, 1 Mette
More informationORIGINAL ARTICLE. Editorial p Methods. Heart Failure
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Heart Failure Low Systolic Blood Pressure on Admission Predicts Mortality in Patients With
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationKaren A. Hicks, M.D. Medical Officer Division of Cardiovascular and Renal Products Center for Drug Evaluation and Research, FDA
Karen A. Hicks, M.D. Medical Officer Division of Cardiovascular and Renal Products Center for Drug Evaluation and Research, FDA Click to view Biosketch and Presentation Abstract or page down to review
More informationUsing Lung Ultrasound to Diagnose and Manage Acute Heart Failure
Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Jennifer Martindale, MD Assistant Professor Department of Emergency Medicine SUNY Downstate/Kings County Hospital Brooklyn, NY What is acute
More informationClinical material and methods. Fukui Cardiovascular Center, Fukui, Japan
Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Contribution of Extracardiac Factors to the Inconsistency Between Plasma B-type Natriuretic Peptide Levels and the Severity of Pulmonary Congestion on Chest X-rays in the Diagnosis of
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationBrief View of Calculation and Measurement of Cardiac Hemodynamics
Cronicon OPEN ACCESS EC CARDIOLOGY Review Article Brief View of Calculation and Measurement of Cardiac Hemodynamics Samah Alasrawi* Pediatric Cardiologist, Al Jalila Children Heart Center, Dubai, UAE *
More informationPlasma MR-proADM is superior to NTproBNP for all-cause short term mortality prediction in acute pulmonary embolism.
J. Pedowska-Wloszek, M. Kostrubiec, A. Labyk, S. Pacho, O. Dzikowska-Diduch, P. Bienias, B. Lichodziejewska, P. Palczewski, M. Ciurzynski, P. Pruszczyk Plasma MR-proADM is superior to NTproBNP for all-cause
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More informationAcute heart failure, beyond conventional treatment: persisting low output
Acute heart failure, beyond conventional treatment: persisting low output Alexandre Mebazaa, FESC Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts
More informationEchocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction
Echocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction October 4, 2014 James S. Lee, M.D., F.A.C.C. Associates in Cardiology, P.A. Silver Spring, M.D. Disclosures Financial none
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More information2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland
2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,
More informationClinical Outcome in Patients with Aortic Stenosis
Clinical Outcome in Patients with Aortic Stenosis Is the Prognosis Worse in Patients with Low-Gradient Severe Aortic Stenosis? Yoel Angel BSc, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc,
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationThe Treatment Targets in Acute Decompensated Heart Failure
SUCCESS WITH HEART FAILURE The Treatment Targets in Acute Decompensated Heart Failure Gregg C. Fonarow, MD The Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationRight Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa
Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa 1 Ojji Dike B, Lecour Sandrine, Atherton John J, Blauwet Lori A, Alfa Jacob, Sliwa
More informationLow ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients
Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients N. Peltz-Sinvani, MD 1,4,R.Klempfner,MD 2,4, E. Ramaty, MD 1,4,B.A.Sela,PhD 3,4,I.Goldenberg,MD
More informationΜαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό
Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling
More informationLV Distension and ECLS Lungs
LV Distension and ECLS Lungs Kevin W. Hatton, MD, FCCM Interim Vice-Chair for Anesthesiology Research Division Chief, Anesthesiology Critical Care Medicine Program Director, Anesthesiology Critical Care
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationRuolo della ablazione della fibrillazione atriale nello scompenso cardiaco
Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria
More informationAssessment and Diagnosis of Heart Failure
Assessment and Diagnosis of Heart Failure Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood and is characterized
More informationSCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA
Journal Club 19 Marzo 2010 SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA Alessandro Giordano Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007 Incidence of heart failure by age
More informationStudy of grading of severity of Heart Failure in patients with Dilated Cardiomyopathy
Original article: Study of grading of severity of Heart Failure in patients with Dilated Cardiomyopathy Dr Satyajeet Shantaram Nighute *, Dr Govind S. Shiddapur, Dr Madhulika Mahashaabde, Dr Chintan K.
More informationClinical Significance of Plasma Ammonia in Patients with Generalized Convulsion
ORIGINAL ARTICLE Clinical Significance of Plasma Ammonia in Patients with Generalized Convulsion Kouichi Tomita 1,NorioOtani 2,FumioOmata 3,4 and Shinichi Ishimatsu 1,2 Abstract Background Plasma ammonia
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationJournal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationThe Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities
The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationThe right ventricle in chronic heart failure
The right ventricle in chronic heart failure ESC 2012 Christian Opitz, Berlin There are no conflicts of interest relevant to this presentation Percent of Population Prevalence of Heart Failure by Age and
More informationJournal of the American College of Cardiology Vol. 37, No. 1, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01102-5 Independent
More informationHepcidin as a Novel Biomarker of Congestive Hepatopathy in Advanced Heart Failure Patients
Christine J. Chung Doris Duke Clinical Research Fellow 7/7/2011 Hepcidin as a Novel Biomarker of Congestive Hepatopathy in Advanced Heart Failure Patients I. Study Purpose and Rationale Background: Heart
More informationPortable Sleep Testing in Hospitalized Patients
1 Portable Sleep Testing in Hospitalized Patients Rami Khayat, MD Heart Failure AND Public Health 6 million Americans with heart failure (>2% population 20 million people with asymptomatic cardiac impairment
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationRehospitalization Prognostic Factors in Patients with Heart Failure: a Prospective Follow-up Study
ARC Journal of Cardiology Volume2, Issue 2, 2016, PP 13-18 ISSN No. (Online) 2455-5991 http://dx.doi.org/10.20431/2455-5991.0202002 www.arcjournals.org Rehospitalization Prognostic Factors in Patients
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease Etiology General Principles Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information